Standards & guidance

Filter Standards and Guidance documents

Page 1 of 13

FSRH CEU Statement: Extended use of all 52mg LNG-IUDs for up to eight years for contraception (May 2024)

09 May 2024

Following the change in licence of Mirena® to eight years, the CEU have reconvened the Intrauterine Contraception (IUC) Guideline Development Group (GDG) to consider the extended use of all 52mg LNG-IUDs to eight years for contraception. Overall, whilst the evidence is limited, the GDG felt there was sufficient evidence to make the following recommendations.

You are welcome to download our freely available Guideline documents by clicking on the document title above.

This document is up-to-date

FSRH Service Standards for Vasectomy (April 2024)

15 April 2024

Read and download the FSRH Service Standards for Vasectomy in Sexual and Reproductive Healthcare Services, published in April 2024. 

You are welcome to download our freely available Guideline documents by clicking on the document title above.

This document is up-to-date

FSRH CEU Statement: Mirena 8 years contraception (Jan 2024)

11 January 2024

This CEU statement notes that the Mirena® 52mg LNG-IUD has now been licensed for 8 years for contraception. There has not been an extension to the licensed duration of use when being used for the management of heavy menstrual bleeding, or for endometrial protection as part of hormone replacement therapy.    This supersedes the current advice in the Intrauterine Contraception Guideline.

You are welcome to download our freely available Guideline documents by clicking on the document title above.

This document is up-to-date

FSRH CEU Statement: Drospirenone Progestogen-only Pill (DRSP POP) (Jan 24)

10 January 2024

This CEU statement provides a brief summary of key information on a new drospirenone progestogen-only pill (DRSP POP) Slynd® available now in the UK.

You are welcome to download our freely available Guideline documents by clicking on the document title above.

This document is up-to-date

FSRH CEU Statement: Response to new study by Meaidi et al (2023) Venous thromboembolism with use of hormonal contraception and non-steroidal anti-inflammatory drugs

07 September 2023

This FSRH Statement responses to a recently published study by Meaidi et al. published on 06/09/2023 which used data from nationwide Danish databases to compare risk of first VTE events during use of hormonal contraception (HC) with that during concomitant use of HC and the non-steroidal anti-inflammatory drugs (NSAIDs) ibuprofen, diclofenac or naproxen.

You are welcome to download our freely available Guideline documents by clicking on the document title above.

This document is up-to-date